On the positive side, good safety data continuing and suggestions that it could work with mk-0518 (or whatever it's new silly name is).
Negative news I guess was one arm of the trial participants had a reduction in viral load of 0.55 log, so less than avexa's target. But we sort have guessed something like that.
The sp is still struggling to shake off the shackles of the 53c raising effect. I'm hoping to be in sub 70c if I can.
AVX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
